Key points are not available for this paper at this time.
Background Lasmiditan offers a promising option for the treatment of migraines, particularly for individuals with cardiovascular concerns. It is crucial to gather comprehensive safety information of lasmiditan through large-scale post market monitoring.
Wan et al. (Thu,) studied this question.